A flow cytometry reagent for detecting G-CSFR and its preparation method and application

By connecting fluorescein to human recombinant G-CSF to form a flow detection reagent with high affinity combination, the problem of signal binding failure caused by mutation of surface antigen in the G-CSFR in the prior art is solved, and the G-CSFR is realized Accurate detection fills the gap in the existing technology and has good application prospects.

CN114755165BInactive Publication Date: 2024-11-22THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210423390.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-21
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing flow detection reagents are unable to effectively detect signal binding failure caused by mutations in the surface of G-CSFR, limiting medical research and clinical applications.

Method used

Using a fluorescent labeled flow detection reagent based on cytokine G-CSF, a high-affinity combination is formed by connecting fluorescein to human recombinant G-CSF, which can maintain effective detection when the receptor mutation occurs.

Benefits of technology

This reagent can accurately detect G-CSFR on the cell surface, make up for the shortcomings of the prior art, have good application prospects, and can be comparable to the detection effect of CD114 antibody, and is suitable for detecting G-CSFR expression on the surface of leukemia cells in AML patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114755165B_ABST
    Figure CN114755165B_ABST
Patent Text Reader

Abstract

The present invention provides a flow detection reagent for detecting G-CSFR, wherein the active ingredient is human recombinant G-CSF connected with fluorescein. The present invention also provides a corresponding preparation method and a detection kit prepared based on the flow detection reagent. The present invention makes up for the defect that the existing flow detection is mainly based on antibodies, fills the gap in the existing technology, and has good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical diagnosis technology, and in particular to a flow detection reagent for detecting G-CSFR and a preparation method and application thereof. Background Art

[0002] Granulocyte colony stimulating factor (G-CSF) is a cell growth factor produced by monocytes and macrophages. It activates a complex signal transduction system by binding to the specific receptor G-CSFR on the surface of effector cells, and exerts multiple biological functions, including regulating the proliferation, differentiation and survival of myeloid cells. At present, G-CSF is widely used in clinical practice for granulocytopenic diseases and symptoms of granulocytopenia after chemotherapy. G-CSF is also a powerful mobilizer of peripheral blood stem cells during autologous or allogeneic transplantation. In addition, the pre-stimulation regimen of G-CSF combined with chemotherapy has also achieved good results in the treatment of refractory, relapsed, elderly acute myeloid leukemia and myelodysplastic syndrome.

[0003] G-CSFR is a high-affinity receptor distributed in myeloid-directed hematopoietic progenitor cells, neutrophils, endothelial cells, myeloid leukemia cells, some immature lymphocytes, T lymphocytes, B lymphocytes and some non-hematopoietic cells. Under normal circumstances, G-CSFR binds to G-CSF, which can promote the growth and maintenance of myeloid precursor cells and promote the final differentiation of myeloid cells into granulocytes. However, abnormal expression and gene mutation of G-CSFR can lead to disordered signal transduction of G-CSF, which is usually closely related to the occurrence and development of malignant congenital neutropenia, acute myeloid leukemia, chronic neutrophilic leukemia, atypical chronic myeloid leukemia and other diseases. In recent years, with the deepening of molecular genetics and clinical research, many new advances have been made in the study of the specific role of abnormal expression or gene mutation of G-CSFR in the pathogenesis and treatment of related blood diseases. However, due to the limitations of detection methods, the diversity of patients, the biological and genetic heterogeneity of blood tumor cells and other factors, some research reports on G-CSFR are still controversial, and the relationship between G-CSFR and clinical diagnosis, treatment and prognosis needs to be further explored.

[0004] Flow cytometry is a classic single-cell detection technology that can perform multi-parameter detection of cell surface markers. Traditional flow cytometry uses fluorescent group-coupled antibodies, and based on the specific binding characteristics of antibodies and cell surface antigens, uses fluorescent light paths to detect cell surface markers. However, this technology also has limitations, that is, mutations in cell surface antigens may cause the binding of the corresponding antibodies to fail, making it impossible for flow cytometry to detect the signal of cell surface markers binding to antibodies. Currently, all flow detection reagents on the market are prepared from antibodies, and the problem of antigen mutation cannot be avoided, which greatly limits medical research and clinical applications. Summary of the invention

[0005] The present invention aims at the technical problems existing in the above-mentioned prior art and provides a flow detection reagent for detecting G-CSFR based on the cytokine G-CSF. Cytokines are mostly low-molecular-weight proteins or glycoproteins, and have high affinity with cytokine receptors, which is 100-1000 times the affinity of antigen-antibody, and the binding between the two is complete, and mutation of the receptor has no effect on the binding between the two. The reagent makes up for the defect of the existing flow detection that is mainly based on antibodies, fills the gap in the existing technology, and has good application prospects.

[0006] The present invention first provides a flow detection reagent for detecting G-CSFR, wherein the active ingredient is human recombinant G-CSF connected with fluorescein; the fluorescein is selected from any one of fluorescein isothiocyanate (FITC), phycoerythrin (PE) or allophycocyanin (APC).

[0007] In one embodiment of the present invention, the amino acid sequence of the human recombinant G-CSF is SEQ ID NO: 1.

[0008] Sequence SEQ ID NO:1

[0009]

[0010] In one embodiment according to the present invention, the invention further comprises a solvent, and the solvent is PBS.

[0011] The present invention also provides a method for preparing the above-mentioned flow detection reagent, comprising:

[0012] 1) Mix FITC reagent and MES to obtain a mixed solution with a FITC concentration of 10 mg / mL;

[0013] 2) adding excess EDC and NHS to the mixed solution, mixing well and reacting at room temperature for 15 minutes;

[0014] 3) adding mercaptoethanol to terminate the EDC activation reaction, and adjusting the pH to 7.2 to obtain an activated mixed solution;

[0015] 4) Add the recombinant human G-CSF protein to the activated mixed solution, mix thoroughly, and react at room temperature for 2 hours; the molar ratio of the G-CSF protein to FITC is 1:1.

[0016] 5) Add an appropriate amount of hydroxylamine hydrochloride, and then dialyze in 1× PBS overnight to obtain the product.

[0017] The present invention further provides a kit for detecting G-CSFR, which comprises the above-mentioned detection reagent.

[0018] The beneficial effects of the above technical solution of the present invention are as follows:

[0019] The detection reagent for detecting G-CSFR provided by the present invention has a detection effect comparable to that of CD114 antibody, and accurately detects G-CSFR on the cell surface. At the same time, the present invention makes up for the defect that the existing flow cytometry detection is mainly based on antibodies, fills the gap in the existing technology, and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is a graph showing the results of using G-Reagent to detect normal hematopoietic stem cells and leukemia cells;

[0021] Figure 2 This is a comparison chart of the detection effects of G-Reagent and CD114;

[0022] Figure 3 This is the expression profile of CD114 and G-CSFR on the surface of CD34+ malignant primitive cells in AML patients;

[0023] Figure 4 T-test statistical correlation graph of the difference between G-Reagent and CD114 in detecting G-CSFR. DETAILED DESCRIPTION

[0024] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.

[0025] Reagents and instruments

[0026] Recombinant human G-CSF (purchased from Xiamen Tebao Bioengineering Co., Ltd.)

[0027] FITC (fluorescein isothiocyanate) (Beijing Solebao Company)

[0028] MES (Morpholineethanesulfonic acid) (Beijing Solaibao Company)

[0029] NHS (N-hydroxysuccinimide) (Beijing Solebao Company)

[0030] EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) (Beijing Solaibao Company)

[0031] NaHCO3 (Beijing Solebow Company)

[0032] Hydroxylamine hydrochloride (Beijing Solaibao Company)

[0033] Red blood cell lysis buffer (Coulter-Beckman, USA)

[0034] Cell line K562 (cultured and stored in the School of Laboratory Medicine, Chongqing Medical University)

[0035] Antibody CD114 (Biolegend, USA)

[0036] Flow cytometer (Coulter-Beckman, USA)

[0037] Example 1 G-Reagent Preparation

[0038] The preparation method is based on recombinant human G-CSF (Xiamen Tebao Bioengineering Co., Ltd.) and fluorescent groups as raw materials, and the fluorescent groups are connected to G-CSF, including the following steps:

[0039] 1) Return all reagents and recombinant human G-CSF protein to room temperature and re-dissolve. Take 50 μL of 20 mg / mL FITC reagent, add 50 μL of pH 6.0 MES, mix well and make it into 10 mg / mL.

[0040] 2) Weigh 0.1g EDC and dissolve it in 500μL pure water. Weigh 0.1g NHS and dissolve it in 1mL pure water. Add 4μL EDC and 10μL NHS to FITC reagent respectively, mix well, and react at room temperature for 15min.

[0041] 3) Add 1.4 μL of mercaptoethanol to terminate the EDC activation reaction and adjust the pH to 7.2 with 1 M NaHCO3.

[0042] 4) Add 0.5 mg of recombinant human G-CSF protein to the above FITC reagent, mix thoroughly, and react at room temperature for 2 h.

[0043] 5) Add 12.4 μL of 1M hydroxylamine hydrochloride. Dialyze overnight with 1×PBS. After dialysis, collect and aliquot, and store at -80℃ in the dark.

[0044] Example 2 Detection of normal hematopoietic stem cells and leukemia cells by G-Reagent

[0045] 1) Pre-treat the patient's specimens. According to the degree of bone marrow hyperplasia of the patient, take 30-50 μL of bone marrow fluid into a test tube, add 2 mL of PBS to wash and centrifuge to discard the supernatant, and repeat once.

[0046] 2) Add the prepared G-CSFR detection reagent in a concentration gradient and incubate at room temperature in the dark for 15 minutes.

[0047] 3) Add 200 μL of red blood cell lysis buffer and lyse for 15 min in the dark.

[0048] 4) Add 2 mL of PBS to wash and centrifuge to discard the supernatant.

[0049] 5) Repeat the previous step.

[0050] 6) Add 200 μL PBS to re-select the cell pellet, and use flow cytometry to detect the expression of G-CSFR.

[0051] Blank group and 0.25μg / μL-8μg / μL concentration gradient group were set up to detect the effect of different concentrations of G-CSF flow cytometry reagent on the detection rate of G-CSFR. G-CSF flow cytometry reagent was added to the above groups, incubated at room temperature for 15 minutes, and flow cytometry was performed on the surface of bone marrow cells of acute leukemia (AML) patients.

[0052] Experimental results:

[0053] G-CSFR on the surface of normal hematopoietic stem cells was detected by flow cytometry using G-Reagent ( Figure 1 In Figures A and B), it was found that normal hematopoietic stem cells do not express G-CSFR on their surface, whereas leukemia cells in AML patients express high levels of G-CSFR ( Figure 1 A total of 149 bone marrow specimens from newly diagnosed or relapsed AML patients and 60 bone marrow specimens from normal subjects or anemic patients were tested, and the percentage of cells expressing G-CSFR was counted. The results were ( Figure 1 Middle E) shows that the G-CSFR expression level in AML patients is significantly higher than that in normal people, and the difference is statistically significant (P<0.001), indicating that G-CSFR is abnormally highly expressed on the surface of leukemia stem cells in AML patients.

[0054] Example 3 Comparison of detection effects between G-Reagent and CD114

[0055] Since chronic myeloid leukemia is a chronic proliferative tumor characterized by abnormal proliferation of middle and late myelocytes, the cell morphology and phenotype of its cell line K562 also conform to the characteristics of middle and late myelocytes. Therefore, chronic myeloid leukemia cell line K562 was selected as the experimental object to compare the detection effect of G-Reagent and the corresponding antibody reagent CD114.

[0056] 1) Culture K562 cells to the logarithmic growth phase and count 1x10 5 / mL cells in two groups of test tubes, centrifuge and discard the supernatant, add 2mL PBS to resuspend the cell pellet, wash and centrifuge again, discard the supernatant, and repeat once.

[0057] 2) The two groups of test tubes were added with the prepared G-CSFR detection reagent in a concentration gradient and the corresponding antibody control CD114 in a concentration gradient, and incubated at room temperature in the dark for 15 minutes.

[0058] 3) Add 2 mL of PBS for washing and centrifuge to discard the supernatant.

[0059] 4) Repeat the previous step.

[0060] 5) Add 200 μL PBS to re-select the cell pellet, and use flow cytometry to detect the expression of G-CSFR and the corresponding antibody CD114 on the surface of K562 cells.

[0061] The results are as follows Figure 2 As shown, Figure 2 A is the expression level of G-CSFR on the surface of K562 cells in the blank control group without G-Reagent detected by flow cytometry. Figure 2 B is a flow cytometry analysis of the expression level of G-CSFR on the surface of K562 cells to which 2 μg / μL of G-Reagent was added. The results show that G-Reagent can detect the expression of G-CSFR on the surface of K562 cells. Figure 2 C and D are G-Reagent and antibody CD114 controls (blank group and CD114, respectively). Figure 2 E) It can be found that there is a good linear correlation between G-Reagent and antibody CD114, which can accurately detect G-CSFR on the cell surface.

[0062] Example 4

[0063] By testing a large number of clinical AML specimens and based on FAB typing, the expression of G-CSFR in AML patients was detected by G-Reagent and CD114 antibody.

[0064] Table 1 Description of continuous variables of G-Reagent and CD114

[0065]

[0066] Table 2 Baseline table of AML patients detected by G-Reagent and CD114

[0067]

[0068] The results are shown in Table 1, Table 2, Figure 3 and Figure 4 As shown, there was no difference in the expression of G-CSFR in AML patient specimens detected by G-Reagent compared with CD114.

[0069] When the applicant used the G-CSF flow cytometry reagent to detect the expression of G-CSFR on the surface of malignant primitive cells of AML patients, it was found that it was difficult to detect the expression of G-CSFR in a small number of AML patients using the antibody CD114 ( Figure 3 A, 3B), but the expression of G-CSFR can be detected using G-CSF flow cytometry reagent ( Figure 3 C, 3D), indicating that the G-CSFR of the patient's leukemia cells may have mutated, resulting in the inability of the antibody to effectively bind and detect the expression of G-CSFR. The G-CSF flow cytometry reagent uses a complete cytokine to bind to the complete G-CSF receptor, and can specifically bind to the cytokine regardless of whether the G-CSFR is mutated or not.

[0070] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention. Sequence Listing <110> The Second Affiliated Hospital of Chongqing Medical University <120> A flow cytometry reagent for detecting G-CSFR and its preparation method and application <141> 2022-04-21 <160> 1 <170> SIPOSequenceListing 1.0 <210> 1 <211> 863 <212> PRT <213> Artificial Sequence <400> 1 Met Ala Arg Leu Gly Asn Cys Ser Leu Thr Trp Ala Ala Leu Ile Ile 1 5 10 15 Leu Leu Leu Pro Gly Ser Leu Glu Glu Cys Gly His Ile Ser Val Ser 20 25 30 Ala Pro Ile Val His Leu Gly Asp Pro Ile Thr Ala Ser Cys Ile Ile 35 40 45 Lys Gln Asn Cys Ser His Leu Asp Pro Glu Pro Gln Ile Leu Trp Arg 50 55 60 Leu Gly Ala Glu Leu Gln Pro Gly Gly Arg Gln Gln Arg Leu Ser Asp 65 70 75 80 Gly Thr Gln Glu Ser Ile Ile Thr Leu Pro His Leu Asn His Thr Gln 85 90 95 Ala Phe Leu Ser Cys Cys Leu Asn Trp Gly Asn Ser Leu Gln Ile Leu 100 105 110 Asp Gln Val Glu Leu Arg Ala Gly Tyr Pro Pro Ala Ile Pro His Asn 115 120 125 Leu Ser Cys Leu Met Asn Leu Thr Thr Ser Ser Leu Ile Cys Gln Trp 130 135 140 Glu Pro Gly Pro Glu Thr His Leu Pro Thr Ser Phe Thr Leu Lys Ser 145 150 155 160 Phe Lys Ser Arg Gly Asn Cys Gln Thr Gln Gly Asp Ser Ile Leu Asp 165 170 175 Cys Val Pro Lys Asp Gly Gln Ser His Cys Cys Ile Pro Arg Lys His 180 185 190 Leu Leu Leu Tyr Gln Asn Met Gly Ile Trp Val Gln Ala Glu Asn Ala 195 200 205 Leu Gly Thr Ser Met Ser Pro Gln Leu Cys Leu Asp Pro Met Asp Val 210 215 220 Val Lys Leu Glu Pro Pro Met Leu Arg Thr Met Asp Pro Ser Pro Glu 225 230 235 240 Ala Ala Pro Pro Gln Ala Gly Cys Leu Gln Leu Cys Trp Glu Pro Trp 245 250 255 Gln Pro Gly Leu His Ile Asn Gln Lys Cys Glu Leu Arg His Lys Pro 260 265 270 Gln Arg Gly Glu Ala Ser Trp Ala Leu Val Gly Pro Leu Pro Leu Glu 275 280 285 Ala Leu Gln Tyr Glu Leu Cys Gly Leu Leu Pro Ala Thr Ala Tyr Thr 290 295 300 Leu Gln Ile Arg Cys Ile Arg Trp Pro Leu Pro Gly His Trp Ser Asp 305 310 315 320 Trp Ser Pro Ser Leu Glu Leu Arg Thr Thr Glu Arg Ala Pro Thr Val 325 330 335 Arg Leu Asp Thr Trp Trp Arg Gln Arg Gln Leu Asp Pro Arg Thr Val 340 345 350 Gln Leu Phe Trp Lys Pro Val Pro Leu Glu Glu Asp Ser Gly Arg Ile 355 360 365 Gln Gly Tyr Val Val Ser Trp Arg Pro Ser Gly Gln Ala Gly Ala Ile 370 375 380 Leu Pro Leu Cys Asn Thr Thr Glu Leu Ser Cys Thr Phe His Leu Pro 385 390 395 400 Ser Glu Ala Gln Glu Val Ala Leu Val Ala Tyr Asn Ser Ala Gly Thr 405 410 415 Ser Arg Pro Thr Pro Val Val Phe Ser Glu Ser Arg Gly Pro Ala Leu 420 425 430 Thr Arg Leu His Ala Met Ala Arg Asp Pro His Ser Leu Trp Val Gly 435 440 445 Trp Glu Pro Pro Asn Pro Trp Pro Gln Gly Tyr Val Ile Glu Trp Gly 450 455 460 Leu Gly Pro Pro Ser Ala Ser Asn Ser Asn Lys Thr Trp Arg Met Glu 465 470 475 480 Gln Asn Gly Arg Ala Thr Gly Phe Leu Leu Lys Glu Asn Ile Arg Pro 485 490 495 Phe Gln Leu Tyr Glu Ile Ile Val Thr Pro Leu Tyr Gln Asp Thr Met 500 505 510 Gly Pro Ser Gln His Val Tyr Ala Tyr Ser Gln Glu Met Ala Pro Ser 515 520 525 His Ala Pro Glu Leu His Leu Lys His Ile Gly Lys Thr Trp Ala Gln 530 535 540 Leu Glu Trp Val Pro Glu Pro Pro Glu Leu Gly Lys Ser Pro Leu Thr 545 550 555 560 His Tyr Thr Ile Phe Trp Thr Asn Ala Gln Asn Gln Ser Phe Ser Ala 565 570 575 Ile Leu Asn Ala Ser Ser Arg Gly Phe Val Leu His Gly Leu Glu Pro 580 585 590 Ala Ser Leu Tyr His Ile His Leu Met Ala Ala Ser Gln Ala Gly Ala 595 600 605 Thr Asn Ser Thr Val Leu Thr Leu Met Thr Leu Thr Pro Glu Gly Ser 610 615 620 Glu Leu His Ile Ile Leu Gly Leu Phe Gly Leu Leu Leu Leu Leu Thr 625 630 635 640 Cys Leu Cys Gly Thr Ala Trp Leu Cys Cys Ser Pro Asn Arg Lys Asn 645 650 655 Pro Leu Trp Pro Ser Val Pro Asp Pro Ala His Ser Ser Leu Gly Ser 660 665 670 Trp Val Pro Thr Ile Met Glu Glu Leu Pro Gly Pro Arg Gln Gly Gln 675 680 685 Trp Leu Gly Gln Thr Ser Glu Met Ser Arg Ala Leu Thr Pro His Pro 690 695 700 Cys Val Gln Asp Ala Phe Gln Leu Pro Gly Leu Gly Thr Pro Pro Ile 705 710 715 720 Thr Lys Leu Thr Val Leu Glu Glu Asp Glu Lys Lys Pro Val Pro Trp 725 730 735 Glu Ser His Asn Ser Ser Glu Thr Cys Gly Leu Pro Thr Leu Val Gln 740 745 750 Thr Tyr Val Leu Gln Gly Asp Pro Arg Ala Val Ser Thr Gln Pro Gln 755 760 765 Ser Gln Ser Gly Thr Ser Asp Gln Val Leu Tyr Gly Gln Leu Leu Gly 770 775 780 Ser Pro Thr Ser Pro Gly Pro Gly His Tyr Leu Arg Cys Asp Ser Thr 785 790 795 800 Gln Pro Leu Leu Ala Gly Leu Thr Pro Ser Pro Lys Ser Tyr Glu Asn 805 810 815 Leu Trp Phe Gln Ala Ser Pro Leu Gly Thr Leu Val Thr Pro Ala Pro 820 825 830 Ser Gln Glu Asp Asp Cys Val Phe Gly Pro Leu Leu Asn Phe Pro Leu 835 840 845 Leu Gln Gly Ile Arg Val His Gly Met Glu Ala Leu Gly Ser Phe 850 855 860

Claims

1. A flow cytometry detection reagent for detecting G-CSFR, characterized in that: The active ingredient is human recombinant G-CSF connected with fluorescein; the fluorescein is fluorescein isothiocyanate FITC.

2. The flow detection reagent according to claim 1, characterized in that The amino acid sequence of the human recombinant G-CSF is SEQ ID NO:

1.

3. The flow detection reagent according to claim 1 or 2, characterized in that: The invention also comprises a solvent, which is PBS.

4. The flow detection reagent according to claim 1, characterized in that The fluorescein may also be phycoerythrin PE or allophycocyanin APC.

5. The method for preparing a flow detection reagent according to any one of claims 1 to 3, characterized in that: include: 1) Mix FITC reagent and MES to obtain a mixed solution with a FITC concentration of 10 mg / mL; 2) adding excess EDC and NHS to the mixture, mixing well and reacting at room temperature for 15 min; 3) Add mercaptoethanol to terminate the EDC activation reaction, and adjust the pH to 7.2 to obtain an activated mixed solution; 4) Add the recombinant human G-CSF protein to the activated mixed solution, mix thoroughly, and react at room temperature for 2 hours; the molar ratio of the G-CSF protein to FITC is 1:1; 5) Add an appropriate amount of hydroxylamine hydrochloride, and then dialyze in 1× PBS overnight to obtain the product.

6. A kit for detecting G-CSFR, characterized in that: Contains the detection reagent as described in any one of claims 1-3.